- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Thiogenesis Therapeutics Corp: Thiogenesis CTA accepted by EMA for MELAS trial | 1 | Stockwatch | ||
| 25.03. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS | 253 | Newsfile | San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
| 20.12.23 | Thiogenesis Therapeutics Corp: Thiogenesis closes $312,750 final tranche of financing | 3 | Stockwatch | ||
| 20.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement | 341 | Newsfile | San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release... ► Artikel lesen | |
| 18.12.23 | Thiogenesis Therapeutics Corp: Thiogenesis closes $4.18-million private placement | 3 | Stockwatch | ||
| 17.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation | 151 | Newsfile | San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very... ► Artikel lesen | |
| 04.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium | 557 | Newsfile | San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing... ► Artikel lesen | |
| 27.11.23 | Thiogenesis Therapeutics Corp: Thiogenesis appoints Stanton as scientific adviser | 2 | Stockwatch | ||
| 27.11.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board | 494 | Newsfile | San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing... ► Artikel lesen | |
| 20.11.23 | Thiogenesis Therapeutics Corp: Thiogenesis arranges $4.5-million private placement | 3 | Stockwatch | ||
| 20.11.23 | Thiogenesis Therapeutics to raise $4.5M through private placement | 1 | Seeking Alpha | ||
| 20.11.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Non-Brokered Private Placement of Common Shares | 612 | Newsfile | San Diego, California--(Newsfile Corp. - November 20, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private... ► Artikel lesen | |
| 10.05.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Therapeutics Reports on Full Year 2022 Financial Results and Provides Corporate Update | 298 | Newsfile | San Diego, California--(Newsfile Corp. - May 10, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing thiol-active compounds... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 52,25 | -0,32 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| JANUX THERAPEUTICS | 55,37 | 0,00 % | Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| QIAGEN | 40,020 | +0,50 % | Qiagen NV-Aktie büßt 0,48 Prozent ein (39,75 €) | Der Anteilsschein von Qiagen NV notiert am Montag ein wenig leichter. Der jüngste Kurs betrug 39,75 Euro. Ein Abschlag von 0,48 Prozent steht gegenwärtig für die Aktie von Qiagen NV zu Buche. Das Papier... ► Artikel lesen | |
| EVOTEC | 9,625 | +0,89 % | Evotec: Neue Kooperation mit Bayer! Was macht die Aktie? | Die Evotec-Aktie ist am 24. April 2024 um ganze 32% eingebrochen, das war der höchste Tagesverlust aller Zeiten für die Aktie des Wirkstoffforschers. Damit summiert sich der Kursverlust in der Sechs-Monats-Betrachtung... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 42,260 | -7,63 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| ADMA BIOLOGICS | 6,860 | -0,72 % | ADMA Biologics, Inc.: ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024 | ||
| BEAM THERAPEUTICS | 22,240 | -1,37 % | Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss | ||
| IMMUNOVANT | 29,760 | 0,00 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
| ZENTALIS PHARMACEUTICALS | 12,430 | +0,73 % | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 27,720 | -5,52 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| NUVALENT | 67,54 | -1,50 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| MORPHOSYS | 66,75 | -0,07 % | Aixtron, K+S, MorphoSys, Siemens Energy, SMA Solar, thyssenkrupp und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,060 | +2,64 % | Avidity Biosciences, Inc.: Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 | Avidity initiating global Phase 3 HARBOR study for delpacibart etedesiran this quarter
Delpacibart etedesiran data from MARINA-OLE showed reversal of disease progression in multiple functional measures... ► Artikel lesen | |
| ARVINAS | 32,370 | -5,60 % | Arvinas Inc.: Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update | - Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 31,700 | +1,18 % | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half... ► Artikel lesen |
THIOGENESIS THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
